Zhou Peng, Wang Qiongren, Wang Chongshan, Li Xiezhao, Du Wei, Liu Chunxiao, Watanabe Masami, Huang Peng, Xu Abai
Department of Urology, Zhujiang Hospital, Southern Medical University Guangzhou, China.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama, Japan.
Int J Clin Exp Pathol. 2017 Oct 1;10(10):10565-10570. eCollection 2017.
The aim of this study was to detect PD-L1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features and patient prognosis. PD-L1 expression was detected in paraffin-embedded sections obtained from 34 patients with bladder rhabdomyosarcoma via immunohistochemistry. Immunohistochemistry results were statistically analyzed to determine their association with patient clinicopathological features and survival outcomes. PD-L1-positive staining was observed in 47.1% (16/34) of patients. Metastatic tumor cells in the lymph nodes of two patients were positive for PD-L1 expression. PD-L1 expression was significantly different with regard to muscularis invasion, but the expression did not affect patient survival outcomes. We confirmed PD-L1 expression in bladder rhabdomyosarcoma, suggesting that PD-1/PD-L1 inhibitors are potential therapeutic agents for patients with bladder rhabdomyosarcoma.
本研究的目的是检测膀胱横纹肌肉瘤中PD-L1的表达及其与临床病理特征和患者预后的相关性。通过免疫组织化学检测了34例膀胱横纹肌肉瘤患者石蜡包埋切片中的PD-L1表达。对免疫组织化学结果进行统计学分析，以确定其与患者临床病理特征和生存结果的相关性。47.1%（16/34）的患者观察到PD-L1阳性染色。两名患者淋巴结中的转移肿瘤细胞PD-L1表达呈阳性。PD-L1表达在肌层浸润方面有显著差异，但该表达不影响患者生存结果。我们证实了膀胱横纹肌肉瘤中PD-L1的表达，提示PD-1/PD-L1抑制剂是膀胱横纹肌肉瘤患者的潜在治疗药物。
